Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

医学 嵌合抗原受体 CD8型 免疫系统 自然杀伤细胞 过继性细胞移植 抗原 淋巴细胞 免疫疗法 癌症研究 免疫学 肿瘤科 内科学 T细胞 细胞毒性T细胞 生物 生物化学 体外
作者
Michael C. Burger,Marie-Thérèse Forster,Annette Romanski,Florian Straßheimer,Jadranka Macas,Pia Susann Zeiner,Eike Steidl,Stefanie C. Herkt,Katharina Johanna Weber,Jonathan Schupp,Jennifer H. Lun,Maja Strecker,Karolin Wlotzka,Pinar Cakmak,Corinna Opitz,Rosemol George,Iris C. Mildenberger,Paulina Nowakowska,Congcong Zhang,Jasmin Röder
出处
期刊:Neuro-oncology [Oxford University Press]
卷期号:25 (11): 2058-2071 被引量:161
标识
DOI:10.1093/neuonc/noad087
摘要

BACKGROUND: Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER2, which is expressed at elevated levels by a subset of glioblastomas. METHODS: Nine patients with recurrent HER2-positive GB were treated with single doses of 1 × 107, 3 × 107, or 1 × 108 irradiated CAR-NK cells injected into the margins of the surgical cavity during relapse surgery. Imaging at baseline and follow-up, peripheral blood lymphocyte phenotyping and analyses of the immune architecture by multiplex immunohistochemistry and spatial digital profiling were performed. RESULTS: There were no dose-limiting toxicities, and none of the patients developed a cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Five patients showed stable disease after relapse surgery and CAR-NK injection that lasted 7 to 37 weeks. Four patients had progressive disease. Pseudoprogression was found at injection sites in 2 patients, suggestive of a treatment-induced immune response. For all patients, median progression-free survival was 7 weeks, and median overall survival was 31 weeks. Furthermore, the level of CD8+ T-cell infiltration in recurrent tumor tissue prior to CAR-NK cell injection positively correlated with time to progression. CONCLUSIONS: Intracranial injection of HER2-targeted CAR-NK cells is feasible and safe in patients with recurrent GB. 1 × 108 NK-92/5.28.z cells was determined as the maximum feasible dose for a subsequent expansion cohort with repetitive local injections of CAR-NK cells.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
2秒前
SherryZhang发布了新的文献求助10
2秒前
陌小石完成签到 ,获得积分0
3秒前
3秒前
顾矜的应助被Bin_Liu采纳,获得10
3秒前
8o7XJ7完成签到,获得积分10
3秒前
3秒前
老鼠人发布了新的文献求助10
4秒前
胡歌完成签到,获得积分10
5秒前
Kia完成签到,获得积分10
6秒前
Chris学长完成签到,获得积分10
7秒前
霸气小土豆完成签到,获得积分10
7秒前
碧淇完成签到,获得积分10
7秒前
puke发布了新的文献求助10
7秒前
Susantong发布了新的文献求助10
8秒前
何秦发布了新的文献求助20
8秒前
wendy完成签到,获得积分10
9秒前
9秒前
9秒前
大模型的应助被Monster采纳,获得10
9秒前
蓓蓓完成签到 ,获得积分10
9秒前
Abracadabra的应助被General采纳,获得20
9秒前
10秒前
10秒前
11秒前
12秒前
田様的应助被内向的太陽采纳,获得10
13秒前
13秒前
drhx完成签到,获得积分10
13秒前
13秒前
励志发SCI完成签到 ,获得积分10
14秒前
15秒前
疯狂硕士完成签到,获得积分10
15秒前
jolly0304发布了新的文献求助10
16秒前
puke完成签到,获得积分10
16秒前
吃猫的鱼发布了新的文献求助10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241